CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression.

ABSTRACT: Lung adenocarcinoma (LUAD) is the most common type of lung cancer. Prolonged treatment of LUAD with 1^st/2^nd generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) promotes the emergence of secondary EGFR T790M mutation conferring resistance to these drugs. Patients who acquire EGFR T790M mutation respond to the 3^rd generation EGFR-TKI osimertinib but develop resistance within 12 months. Circular RNAs (circRNAs) are notably associated with cancerogenesis, making them promising biomarkers or therapeutic targets. In this study, we aimed to identify circRNAs that regulate osimertinib resistance and elucidate the functions and mechanisms to reveal potential therapeutic targets and biomarkers for osimertinib-resistant LUAD. The analysi

SUBMITTER: Verusingam ND 

PROVIDER: S-EPMC12481618 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature